FDA CMC regulations and guidance simplified through examination, real life experiences and risk-based advice. This podcast hopes to educate sponsors and individuals on agency related regulatory CMC matters. We will focus on the critical CMC issues and build programs that enhance drug development. CMC topics will include Regulatory Starting Materials, API and Drug Product Process, Formulation Development, Supply Chains, Analytical Controls. Advocating and interpreting CMC Strategy, directing ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
025 - The Parenteral Drug Association & Evolution of Drug Development with Michael Carroll
31:51
31:51
Play later
Play later
Lists
Like
Liked
31:51
What We Covered 00:55 – Ed, Meranda and Brian welcome today’s guest, Mike Carroll, who speaks to his background in microbiology and product development 04:28 – Mike talks about his involvement in the Parenteral Drug Association (PDA) 07:51 – Lessons Mike has learned throughout his career and expounds on the relevance of PDA technical reports 15:03 …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
024 - Quality Management Systems Explained!
38:59
38:59
Play later
Play later
Lists
Like
Liked
38:59
What We Covered 00:54 – Ed, Meranda and Brian welcome a special panel of guests to break down today’s topic: Quality Management Systems (QMS) Explained! 07:53 – The panel expounds on the timing necessary for QMS and what role the quality manual plays 13:06 – The panel explains the Code of Federal Regulations (CFRs) 17:30 – The panel defines Phase A…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
023 - A Broadway Performance Analogy for API Process Validations with Jim Mencel
43:53
43:53
Play later
Play later
Lists
Like
Liked
43:53
What We Covered 00:52 – Ed, Meranda and Brian welcome back Jim Mencel who shares his extensive experience with process validation 07:46 – The importance of Proven Acceptable Range (PAR) and Critical Process Parameter Program (CPP) 11:14 – The evolution of the batch documentation and the value of critical parameter studies 18:07 – Registration laws …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
022 - Filter Validation & How It Impacts Getting Your Product to Market with Shelli Connelly
32:10
32:10
Play later
Play later
Lists
Like
Liked
32:10
What We Covered 00:51 – Ed, Meranda and Brian introduce today’s guest, Shelli Connelly, who discusses her background and speaks to some of the elements of filter validation 05:41 – Shelli talks about the process of selecting a filter and why not all filters are the same 09:03 – The evolution and importance of sizing filters 11:26 – Shelli speaks to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola
1:00:18
1:00:18
Play later
Play later
Lists
Like
Liked
1:00:18
What We Covered 00:51 – Meranda and Ed discuss the Regulatory Odd Couple blog series and constructing the CTD Module 3 11:54 – Ed explains the importance of building the Quality Overall Summary (QOS) and the different starting points for drug process development 19:45 – Ed and Meranda talk about characterization, the process of manufacturing drug s…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
020 - Lessons Gleaned from Twenty Five Years of a Regulatory CMC Life with Ed Narke
48:13
48:13
Play later
Play later
Lists
Like
Liked
48:13
What We Covered 00:54 – Meranda and Brian flip the script by introducing fellow host, Ed Narke as today’s guest 01:56 – Ed speaks to his extensive background in CMC and the importance he places on building relationships based on trust 11:06 – Ed expounds on his role at DSI and the impact he, Brian, Meranda and the entire DSI team are having on the …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
019 - Complexity of Project Management in Drug Development with Paul Long
43:17
43:17
Play later
Play later
Lists
Like
Liked
43:17
What We Covered 00:55 – Ed, Brian and Meranda welcome to the show Paul Long who shares his well-rounded background as a project management consultant and speaks to some of the benefits and challenges of virtual project management 17:09 – How Paul manages working with clients virtually 19:08 – Tools Paul integrates in his project management process …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
018 - 2020: A Year in Review with Ed Narke, Brian Lihou & Meranda Parascandola
52:38
52:38
Play later
Play later
Lists
Like
Liked
52:38
What We Covered 00:43 – Ed, Brian and Meranda introduce today’s 2020 Year-In-Review show and look back on learnings from Jim Mencel, Dave Adams and Daniel Torok 10:11 – Ed, Brian and Meranda reflect back on their conversations with Rick Offerman, Les Mintzmyer and Dave Blasingame 19:06 – Ed, Brian and Meranda talk about a recent panel discussion th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
017 - 4 Experts, 120+ Years of Drug Substance Experience: Major Trends You Should Know
34:30
34:30
Play later
Play later
Lists
Like
Liked
34:30
What We Covered 01:03 – Ed, Brian and Meranda welcome to the show a panel of drug substance services experts, Daniel Torok, Dave Adams, Jim Mencel and David Blasingame who speak to trends they’ve observed in the landscape of API manufacturing 07:04 – The panel speaks to the types of drug manufacturing requests they’ve been seeing 14:42 – The panel …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
016 - Brexit: What You Need to Know for Drug Development
32:41
32:41
Play later
Play later
Lists
Like
Liked
32:41
What We Covered 00:54 – Ed, Brian and Meranda welcome to the show Amber Sheriff who speaks to her background as a regulatory affairs specialist in the pharmaceutical industry and the three procedures for obtaining market authorization in the European Union 06:15 – What CMC drug development looks like in the EU and how it differs from the United Sta…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
015 - Outsourcing in China: How far can it go?
33:40
33:40
Play later
Play later
Lists
Like
Liked
33:40
What We Covered 00:55 – Ed, Brian and Meranda welcome to the show David Blasingame who speaks to his extensive background as a process chemist as well as the advantages and disadvantages of manufacturing drugs in China 10:20 – The importance of person in-plant activity and the White Coat Effect 11:29 – David speaks to the issues he’s experienced wi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Halloween Special – Ghosts, Spirits and CMC Regulatory, A Halloween Story
49:53
49:53
Play later
Play later
Lists
Like
Liked
49:53
What We Covered 01:12 – Introducing a very spooky Halloween Special where Ed, Brian, Meranda and the rest of the DSI Team share stories of time spent in creepy labs and other scary situations 21:58 – Paul tells a story of working the graveyard shift at a hospital 25:06 – Valerie and Meranda share their own spooky experiences working in pharma 35:01…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
014 - Why now is the most important time for selecting a CMO
48:01
48:01
Play later
Play later
Lists
Like
Liked
48:01
What We Covered 01:19 – Ed, Brian and Meranda welcome to the show Dr. Rick Offerman who speaks to his experience as a process chemist, the drug development process and what goes into selecting a solvent 15:41 – The importance of selecting the right CMO partner 19:05 – Questions that must be asked in the beginning of the drug manufacturing process 2…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
013 - A Discussion on CMC Strategy and Submissions with Ed Narke, Brian Lihou & Meranda Parascandola
41:57
41:57
Play later
Play later
Lists
Like
Liked
41:57
What We Covered 01:16 – Ed, Brian and Meranda take a deep dive into analyzing CMC strategy and submissions 11:26 – Ed, Brian and Meranda discuss resources required for compiling CMC dossiers and the importance of understanding roles and responsibilities within this process 20:09 – Essential aspects of putting together an effective authoring team 25…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
012 - Taking Medicines Back to The Future – A Discussion with Hedley Rees on Value Chain vs. Supply Chain: What's the Difference?
44:38
44:38
Play later
Play later
Lists
Like
Liked
44:38
What We Covered 00:59 – Hedley Rees joins the show to share his background in the pharmaceutical industry, his thoughts on Big Pharma and issues he’s observed with medicine coming to market 09:43 – Hedley speaks to the importance of designing supply chains strategically and why your supply chain is actually your value chain 17:51 – Hedley discusses…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
011 - Hey Google, tell me about the importance of living Development Reports with Kyriakos Michailaros
41:49
41:49
Play later
Play later
Lists
Like
Liked
41:49
What We Covered 00:53 – Kyriakos Michailaros joins the show to share his background and expertise in the subject matter of drug product services 02:59 – Kyriakos shares his thoughts on appropriate timing for a development report, the validation process and the importance of having your development report be a living document 08:53 – Addressing risk…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
010 The White Coat Effect is Real – The Role of Person in Plant Discussion - Daniel Torok
39:40
39:40
Play later
Play later
Lists
Like
Liked
39:40
What We Covered 00:46 – Daniel Torok joins the show to share his experience as a process chemist and collaborating with CMOs in the pharmaceutical industry 07:54 – Daniel speaks to the importance of building trust in order to become an effective in-plant person 19:59 – Daniel details best practices he utilizes for site visits 24:15 – The informatio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
009 Recipes to Build Towards Your NDA/BLA - Ed Narke, Brian Lihou and Meranda Parascandola
50:50
50:50
Play later
Play later
Lists
Like
Liked
50:50
What We Covered 00:44 – Ed, Brian and Meranda join the show to share their experiences in all phases of the pharmaceutical development industry 5:12 – The process of filing an Investigational New Drug (IND) and a New Drug Application (NDA) 18:54 – What it means to have ‘rest-of-world awareness’ as you author an NDA 22:37 – Ed, Brian and Meranda spe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
008 Trust the Process with a CMC Process Champion - Dave Adams
49:26
49:26
Play later
Play later
Lists
Like
Liked
49:26
What We Covered 01:15 – Dave Adams joins the show to discuss his experience with active pharmaceutical ingredients (APIs) and provides examples of how he’s solved problems with APIs in the past 09:41 – What Dave looks for in a comprehensive, well thought out development program and how he works and interacts with process engineers 15:02 – Dave prov…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
007 Selecting a Contract Manufacturing Organization (CMO) - ‘Super’ Les Mintzmyer
45:49
45:49
Play later
Play later
Lists
Like
Liked
45:49
What We Covered 01:32 – Les Mintzmyer joins the show to discuss his background in biologics manufacturing, speak to CMO selection, and break down the RFP process 08:14 – Les speaks to the criteria he uses to identify the best CMO to work with and the importance of timely correspondence 18:59 – Lessons Les has gleaned from the RFP process throughout…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
006 Analytical Method Development - Colman Byrne
50:05
50:05
Play later
Play later
Lists
Like
Liked
50:05
What We Covered 00:43 – Colman Byrne joins the show to discuss his background in analytical chemistry and challenges he’s observed in analytical method development and validation 10:27 – Colman’s recommendations for method development and validation plans 15:04 – Colman speaks to the commonality of changing methods mid-stream 22:01 – Regulatory par…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
005 Pharmaceutical Regulations in CMC - Dr. Catherine Bernard
35:21
35:21
Play later
Play later
Lists
Like
Liked
35:21
What We Covered 03:00 – Dr. Catherine Bernard joins the show to discuss her background in regulatory affairs within the pharmaceutical industry 07:35 – Dr. Catherine speaks to some of the challenges associated with preparing a CMC dossier 10:38 – Dr. Catherine speaks to the vital role project management plays in submissions and explains realistic t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
004 Quality Assurance and Auditing in the Age of Covid-19 - Bettina Kaplan
33:15
33:15
Play later
Play later
Lists
Like
Liked
33:15
What We Covered 02:08 – Bettina Kaplan joins the show to discuss her background in quality assurance, compliance and auditing within the pharmaceutical industry 09:43 – Trends in quality auditing that Bettina observed before the shutdown and strategies to ensure a successful audit 12:48 – Bettina expounds on when it’s appropriate to have an expert,…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
003 Effective Strategies for Early Stage Drug Development - Judy Magruder
28:41
28:41
Play later
Play later
Lists
Like
Liked
28:41
What We Covered 02:10 – Judy Magruder joins the show to discuss her background in early stage drug development and best practices for creating integrated product plans 06:21 – Judy provides her insights on CMC and the importance of identifying effective ways of executing strategy shifts in this ever-changing industry 13:09 – Other communication too…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
002 Establishing Regulatory Starting Materials & Understanding the ICH - James Mencel
35:16
35:16
Play later
Play later
Lists
Like
Liked
35:16
What We Covered 00:54 – James continues his discussion of expedited drug development programs, focusing on the importance of establishing regulatory starting materials 07:34 – James provides best practices for working with clients who don’t want to approach the FDA proactively and curating fallback plans 11:45 – James speaks to strategies for estab…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
001 Expedited Drug Development - James Mencel
18:51
18:51
Play later
Play later
Lists
Like
Liked
18:51
What We Covered 00:23 – James discusses regulations and the importance of starting with big ideas when it comes to expedited drug development programs 05:44 – Breakthrough designations that occur as a result of expedited drug development programs 08:20 – When a sponsor should consider applying for expedited drug development 11:14 – James speaks to …
…
continue reading
Enjoying the show? Please leave us a rating and review at http://ratethispodcast.com/cmcliveBy Ed Narke, Brian Lihou, Meranda Parascandola
…
continue reading